Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Federal Regulators Order Medtronic Inc. to Cease Production and Distribution of Most SynchroMed II Implantable Pump Devices, Parker Waichman LLP Comments
  • USA - English


News provided by

Parker Waichman LLP

Apr 29, 2015, 12:00 ET

Share this article

Share toX

Share this article

Share toX

Federal Regulators Order Medtronic Inc. to Cease Production and Distribution of Most Synchromed II Implantable Pump Devices, Parker Waichman LLP Comments
Federal Regulators Order Medtronic Inc. to Cease Production and Distribution of Most Synchromed II Implantable Pump Devices, Parker Waichman LLP Comments

As a law firm that actively represents numerous individuals who were injured by allegedly defective medical devices, we want to keep consumers up-to-date about recent news involving the Medtronic Synchromed pumps

Post this

Port Washington, New York (PRWEB) April 29, 2015 -- Parker Waichman LLP, a national law firm dedicated to protecting the rights of whistleblowers and victims injured by defective drugs and medical devices, reacts to news that the U.S. Food and Drug Administration has indicated in an April 27, 2014 report that device maker Medtronic Inc. must cease sales of most of its implantable SynchroMed II drug pumps devices following years of problems that went uncorrected. The FDA indicated that it has issued three warning letters to Medtronic concerning quality control and manufacturing problems at its drug pump facility in Columbia Heights, Minnesota, between 2006 and 2013. FDA inspectors visited the plant five times during that time frame, according to the announcement made by federal regulators on April 27, 2015. Some SynchroMed devices have required recalls over loss of battery power, which may lead to device failure, posing significant danger to patients. In some cases, the Medtronic devices over- and under-dosed patients, the FDA indicated in its April 27, 2015 announcement.

Medtronic’s SynchroMed pump devices are surgically implanted pumps meant to deliver medication to an area near the spinal cord and are used to treat patients who have been diagnosed with cancer, severe muscle spasms, and chronic pain, and who do not respond to oral medications or who have suffered severe side effects to oral medications, according to a June 28, 2013 Class I recall announcement issued by the FDA for the SychroMed System.

Also, according to the FDA’s recall database, more than 30 Class I recalls have been issued over the Medtronic SynchroMed system.

A Class I recall designation is the most serious designation issued by the FDA and is indicative of a significant issue that may potentially lead to serious injury, including death, according to Parker Waichman.

“As a law firm that actively represents numerous individuals who were injured by allegedly defective medical devices, we want to keep consumers up-to-date about recent news involving the Medtronic Synchromed pumps,” said Mr. Falkowitz. Parker Waichman LLP comments that it is aware that patients may be harmed during medical procedures and as a result of the use of any medical device and is available to assist those individuals who have suffered injuries related to these procedures and medical device products.

A consent decree is a type of settlement in which a company agrees to court-ordered actions, in this case, Medtronic over its SynchroMed infusion pump system. Guilt or fault is typically not admitted and the decree remains in effect until federal regulators deem the problems detailed in the decree as being resolved, Parker Waichman explained.

“Consent decrees are serious documents that, once approved as actions, enable the FDA to offer stricter oversight over any planned design changes for the device involved, as well as any planned changes by the manufacturer to its quality control processes in manufacturing and distribution,” Gary Falkowitz, Managing Attorney at Parker Waichman noted.

The FDA's consent decree for permanent injunction was filed in the U.S. District Court of Minnesota in collaboration with the U.S. Department of Justice and is pending signature from a federal judge: Case No. 0:15-cv-02168 filed April 27, 2015. Medtronic CEO Omar Ishrak and neuromodulation business chief Thomas Tefft sold medical devices that did not meet federally mandated manufacturing standards under the Food, Drug and Cosmetic Act. According to the government filing, "Defendants are well aware that their practices violate the Act…. FDA has repeatedly warned defendants, both orally and in writing, about their violative conduct."

Parker Waichman is available to assist potential claimants in order to further its investigation of the issues surrounding the Medtronic SynchoMed Pump and continues to offer free lawsuit consultations to victims of injuries due to allegedly defective or unapproved medical devices and procedures. If you or a loved one has been affected by the Medtronic SynchroMed Pump or other medical device you may obtain more information at Parker Waichman LLP. Free case evaluations are also available by calling 1-800-LAW-INFO.

Gary Falkowitz, Parker Waichman LLP, http://yourlawyer.com, +1 (800) 529-4636, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.